This phase requires patience and a willingness to back off if symptoms return
In a Phase 2 clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023), participants using retatrutide experienced up to 24% reduction in body weight over 48 weeks, significantly outperforming earlier GLP-1 agents
Copper supplements - Be carefulGHK-Cu already provides copper
Evaluating semaglutide and tirzepatide in early non-responders While semaglutide produces 15-17% mean weight loss and tirzepatide yields even more impressive 16-22.5% reductions, neither has been thoroughly evaluated in early non-responders
As GLP-1 therapies become a long-term cornerstone in diabetes care, monitoring patients on these treatments is gaining renewed attention
Supplements for Cardiovascular Health While dietary changes are crucial, supplements can also help increase glutathione levels